375 related articles for article (PubMed ID: 31568628)
41. Proteasome Inhibitor Drugs.
Fricker LD
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
[TBL] [Abstract][Full Text] [Related]
42. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
43. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
44. [Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma- Review].
Shi LL; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1576-1579. PubMed ID: 29070146
[TBL] [Abstract][Full Text] [Related]
45. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
46. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
47. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
[TBL] [Abstract][Full Text] [Related]
48. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
49. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Kambhampati S; Wiita AP
Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
[TBL] [Abstract][Full Text] [Related]
50. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
51. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Hu H; Petrosyan A; Osna NA; Liu T; Olou AA; Alakhova DY; Singh PK; Kabanov AV; Faber EA; Bronich TK
J Control Release; 2019 Jul; 306():149-164. PubMed ID: 31121280
[TBL] [Abstract][Full Text] [Related]
52. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
53. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
54. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Besse L; Besse A; Mendez-Lopez M; Vasickova K; Sedlackova M; Vanhara P; Kraus M; Bader J; Ferreira RB; Castellano RK; Law BK; Driessen C
Haematologica; 2019 Sep; 104(9):e415-e419. PubMed ID: 30792209
[No Abstract] [Full Text] [Related]
55. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
56. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Xu Y; Fulciniti M; Samur MK; Ho M; Deng S; Liu L; Wen K; Yu T; Chyra Z; Dereibal S; Zhang L; Yao Y; Chakraborty C; Morelli E; Li N; Lopez MA; Perini T; Mu S; An G; Alonso R; Bianchi G; Tai YT; Anderson KC; Qiu L; Munshi NC
Blood; 2020 Jul; 136(4):468-479. PubMed ID: 32187357
[TBL] [Abstract][Full Text] [Related]
57. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
58. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
59. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
60. Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.
Chen H; Li M; Sanchez E; Wang CS; Lee T; Soof CM; Casas CE; Cao J; Xie C; Udd KA; DeCorso K; Tang GY; Spektor TM; Berenson JR
Mol Cancer Res; 2017 May; 15(5):598-609. PubMed ID: 28122920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
